The present invention relates to a coalescing agent and a coating composition containing the coalescing agent as represented in structure (I); [Formula should be inserted here] wherein; n is integer from 1 to 8; R.sup.1 and R.sup.2 independently represents group selected from alkyl, alkenyl, alkynyl, phenyl, or benzyl groups; and X represents group selected from hydroxy or amine. The coalescing agent according to this invention contains low amount of volatile organic compounds, has no pungent odour, and environmental friendly. Moreover, it provides good efficacy when being used as coating component.

##STR00001##

Provided is a novel liquid crystalline elastomer that can reversibly undergo phase transition between a liquid crystalline phase and an isotropic phase thereof in a relatively low temperature region. A liquid crystalline elastomer precursor comprising a mesogenic group to which an oxide compound is attached, wherein the liquid crystalline elastomer precursor has a molecular moiety excluding the mesogenic group, the molecular moiety having at least one ester bond and at least two active hydrogen groups. A liquid crystalline elastomer comprising the liquid crystalline elastomer precursor cross-linked by a trifunctional or higher-functional isocyanate compound and/or polyol compound, wherein the liquid crystalline elastomer has a molecular moiety excluding the mesogenic group, the molecular moiety having at least one ester bond, and the liquid crystalline elastomer reversibly changes a state thereof between a liquid crystalline phase and isotropic phase thereof in response to a change in temperature thereof.

Biologically active cannabidiol analogs comprising a compound of the formula

##STR00001##

wherein one of R.sub.1 or R.sub.2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R.sub.1 or R.sub.2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R.sub.1 or R.sub.2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

Biologically active cannabidiol analogs comprising a compound of the formula

##STR00001##

wherein one of R.sub.1 or R.sub.2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R.sub.1 or R.sub.2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R.sub.1 or R.sub.2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

A resveratrol ester has the following structure: ##STR00001## R.sup.1, R.sup.2 and R.sup.3 are H or ##STR00002##
Each R.sup.4 is independently a carbon chain of 2 to 4 carbon atoms comprising a terminal carboxylic acid moiety, a carbon chain of 1 to 5 carbon atoms comprising an amine moiety, or ##STR00003##
R.sup.5 is a carbon chain of 3 or 4 carbon atoms having a terminal carboxylic acid moiety. At least one of R.sup.1, R.sup.2 and R.sup.3 is ##STR00004##
Salts of resveratrol esters are also included.

A resveratrol ester has the following structure: ##STR00001## R.sup.1, R.sup.2 and R.sup.3 are H or ##STR00002##
Each R.sup.4 is independently a carbon chain of 2 to 4 carbon atoms comprising a terminal carboxylic acid moiety, a carbon chain of 1 to 5 carbon atoms comprising an amine moiety, or ##STR00003##
R.sup.5 is a carbon chain of 3 or 4 carbon atoms having a terminal carboxylic acid moiety. At least one of R.sup.1, R.sup.2 and R.sup.3 is ##STR00004##
Salts of resveratrol esters are also included.

This document describes biochemical pathways for producing 2,4-pentadienoyl-CoA by forming one or two terminal functional groups, comprised of carboxyl or hydroxyl group, in a C5 backbone substrate such as glutaryl-CoA, glutaryl-[acp] or glutarate methyl ester. 2,4-pentadienoyl-CoA can be enzymatically converted to 1,3-butadiene.

This document describes biochemical pathways for producing 2,4-pentadienoyl-CoA by forming one or two terminal functional groups, comprised of carboxyl or hydroxyl group, in a C5 backbone substrate such as glutaryl-CoA, glutaryl-[acp] or glutarate methyl ester. 2,4-pentadienoyl-CoA can be enzymatically converted to 1,3-butadiene.

Disclosed herein are prodrugs of tapinarof and pharmaceutical formulations comprising tarpinarof, such as oral formulations. Further disclosed herein are methods for treating diseases and disorders of the gastrointestinal tract, skin, eye, lung, and bone joints via the tapinarof prodrugs.

Compounds are of the structure of Formula (II)

##STR00001##

wherein: each X is C(?O); R.sub.1 is a C.sub.1-C.sub.18 alkyl polyol; R.sub.2 is a saccharide group of formula (G).sub.p; G is a monosaccharide residue, where (i) at least one of the OH groups in (G).sub.p is substituted by a halogen atom, and (ii) the saccharide group of formula (G).sub.p is linked to O through a CH.sub.2 group; p is 1 or 2; and m is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. The compounds are effective in treating hepatotoxicity and fatty liver diseases.